Sodium phenylbutyrate
Buphenyl, Ammonaps, Pheburane (sodium phenylbutyrate) is a small molecule pharmaceutical. Sodium phenylbutyrate was first approved as Buphenyl on 1996-04-30. It is used to treat beta-thalassemia, cystic fibrosis, myeloproliferative disorders, and sickle cell anemia in the USA. It has been approved in Europe to treat carbamoyl-phosphate synthase i deficiency disease, citrullinemia, and ornithine carbamoyltransferase deficiency disease.
| Trade Name | Ammonaps, Pheburane |
|---|---|
| Common Name | Sodium phenylbutyrate |
| Indication | beta-thalassemia, carbamoyl-phosphate synthase i deficiency disease, citrullinemia, cystic fibrosis, myeloproliferative disorders, ornithine carbamoyltransferase deficiency disease, sickle cell anemia |
| Drug Class |
